We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
- Authors
Katsaounis, Panagiotis; Kotsakis, Athanasios; Kentepozidis, Nikolaos; Polyzos, Aris; Bakogeorgos, Marios; Koinis, Filippos; Vamvakas, Lambros; Vardakis, Nikolaos; Kalbakis, Kostas; Boukovinas, Ioannis; Varthalitis, Ioannis I.; Prinarakis, Efthimios; Georgoulias, Vassilis; Souglakos, John
- Abstract
Background This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with locally advanced inoperable and metastatic gastric and gastroesophageal junction adenocarcinoma were treated with weekly nab-paclitaxel (150 mg/m² d1, d8, d15 in cycles of 28 days). Results Partial response (PR) was documented in nine patients (23.1%; 95% confidence interval 10.1-37.2%), stable disease (SD) in 11 (28.2%) and disease progression in 18 (46.2%). The disease control rate (SD + PR + complete response) was 51.3%. Grade 3 and 4 neutropenia occurred in 10.2% and 5.1% of patients, respectively; grade 3 anemia in 5.1%; grade 3 neurotoxicity in 5.1%; and grade 2 pain in 5.1%. The median progression-free survival was 3.0 months (range 0.3-13.6) and the median overall survival 6.8 months (range 0.3-22). Conclusion Nab-paclitaxel as second-line treatment in locally advanced inoperable or metastatic gastric and gastroesophageal junction carcinoma is an active chemotherapy regimen with a manageable toxicity profile and merits further evaluation.
- Subjects
STOMACH cancer treatment; PACLITAXEL; CANCER chemotherapy
- Publication
Annals of Gastroenterology, 2018, Vol 31, Issue 1, p65
- ISSN
1108-7471
- Publication type
Article
- DOI
10.20524/aog.2017.0215